Fenofibrate for primary biliary cholangitis with stable cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old and have a BMI between 17 and 28
- Have confirmed primary biliary cholangitis (PBC) based on at least two specific test or history findings
- Have compensated cirrhosis—one or more signs such as imaging/scan findings, endoscopy findings, biopsy results, or certain blood test patterns
- Have been on UDCA for at least 6 months (with a stable dose for the last 3 months) and still have high ALP blood test results
- Have no other major liver diseases and no recent serious complications like uncontrolled confusion or hard-to-control fluid in the belly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This trial tests whether the drug fenofibrate can help people with primary biliary cholangitis (PBC), a chronic liver disease. It is for patients who have already taken fenofibrate in a previous study and want to continue treatment.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
This trial tests a new oral medication, saroglitazar magnesium, for people with Primary Biliary Cholangitis (PBC) who have not improved enough on standard therapy (UDCA) or cannot tolerate it. The goal is to see if it can help control liver enzymes and improve outcomes.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.